Hangzhou Enogen Biotech

Peptide API manufacturer and CDMO in Hangzhou; national high-tech enterprise with 30+ PhDs and 80+ patents. Facility certified by NMPA, US FDA (Green List), EU EDQM, and Korea MFDS. GLP-1 portfolio including Semaglutide (20kg/batch), Tirzepatide, Liraglutide, and Retatrutide with open DMFs and CEPs.

Directory assessment: Hangzhou Enogen Biotech is listed as a CDMO in the peptide supply chain, serving Asia markets from China (Hangzhou). As a direct manufacturer, this supplier controls its own production process from synthesis through purification and quality control release testing. This profile lists 3 sources for reference. This supplier has a medium confidence score — verification signals are present, but the listing is newer or less documented; perform standard due diligence before engaging.